157 related articles for article (PubMed ID: 9849587)
1. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
[TBL] [Abstract][Full Text] [Related]
2. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
4. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
[TBL] [Abstract][Full Text] [Related]
5. Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2006 Dec; 97(12):1396-403. PubMed ID: 16995876
[TBL] [Abstract][Full Text] [Related]
6. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
Hanada M; Noguchi T; Murayama T
Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1055-60. PubMed ID: 9849585
[TBL] [Abstract][Full Text] [Related]
8. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.
Hanada M; Mizuno S; Fukushima A; Saito Y; Noguchi T; Yamaoka T
Jpn J Cancer Res; 1998 Nov; 89(11):1229-38. PubMed ID: 9914793
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
[TBL] [Abstract][Full Text] [Related]
10. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
[TBL] [Abstract][Full Text] [Related]
11. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
[TBL] [Abstract][Full Text] [Related]
15. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
16. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kasai D; Miyazaki M; Maeno K; Sato S
Cancer Chemother Pharmacol; 2011 Sep; 68(3):669-76. PubMed ID: 21128075
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of amrubicin with a 5 day administration schedule in a mouse model].
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Gan To Kagaku Ryoho; 1999 Aug; 26(9):1305-12. PubMed ID: 10478184
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
[TBL] [Abstract][Full Text] [Related]
20. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
